Opportunity Information: Apply for PAR 13 174
Apply for PAR 13 174
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Apr 11, 2013 and posted on Apr 11, 2013.
- Applicants must submit their applications by Jul 10, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Native American tribal governments (Federally recognized) Small businesses County governments State governments Special district governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) (Funding Opportunity Number PAR-13-174) is a National Institutes of Health, National Cancer Institute grant opportunity aimed specifically at centers that already hold certain NCI P50 awards. Rather than funding brand-new centers, this announcement is focused on revision applications (often called supplements or competitive revisions) from currently funded SPOREs (Specialized Programs of Research Excellence) or ICMIC Specialized Centers that are supported through the NCI P50 mechanism. The basic intent is to let established P50 programs add a new, well-justified project that expands what the parent program is already doing, while still staying clearly aligned with the original program theme and goals.
The scientific emphasis is on improving cancer screening, early detection, and diagnostic decision-making by combining imaging and biomarker approaches in a coordinated way. The FOA highlights integration as the core expectation: applicants are supposed to bring together multimodality imaging strategies (for example, using more than one imaging platform or imaging technique in a complementary manner) with multiplexed biomarker methodologies (approaches that can measure multiple biomarkers at once, potentially from blood, tissue, urine, saliva, or other biospecimens). The overall idea is that early cancer detection can be strengthened when imaging signals and biomarker signals are developed, tested, and interpreted as parts of a unified detection strategy rather than as isolated tools. In practical terms, the proposed revision should add an additional project to the existing P50 program that meaningfully broadens the parent award’s scope and capabilities, such as developing new combined imaging-biomarker workflows, validating integrated detection algorithms, improving sensitivity and specificity for early lesions, or refining how imaging and biomarkers together guide diagnosis.
This opportunity is categorized as a discretionary grant, with the activity area tied to cancer detection and diagnosis research (CFDA 93.394). Cost sharing or matching is not required, which means applicants are not expected to provide a formal financial match as a condition of eligibility. The announcement lists an award ceiling of $150,000, indicating the maximum funding amount anticipated under this revision mechanism.
Eligibility is broad in terms of organization type, but narrow in terms of the kind of award you must already have. The applicant organization must be eligible under NIH rules and must be a currently funded SPORE or ICMIC Specialized Center using the NCI P50 mechanism to submit a revision under this FOA. The eligible applicant types listed include public and private institutions of higher education, nonprofits (including 501(c)(3) organizations), state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities/Indian housing authorities, special district governments, and for-profit organizations (including small businesses). The eligibility notes also explicitly include a variety of institution categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and Asian American and Native American Pacific Islander-serving institutions, as well as faith-based or community-based organizations and eligible federal agencies. At the same time, there are clear restrictions on foreign involvement: non-U.S. (foreign) institutions cannot apply, non-U.S. components of U.S. organizations are not eligible, and foreign components are not allowed as defined by the NIH Grants Policy Statement. In short, this is intended to be carried out entirely within eligible U.S.-based organizational structures.
Timing details indicate the FOA was posted and created on April 11, 2013, with an original and current closing date of July 10, 2013, and an archive date of August 10, 2013. That means it was a time-limited announcement and is now archived, but the content still provides a clear picture of what NIH/NCI was looking to support: targeted, additive research projects within existing P50 centers that push early detection forward through tightly integrated imaging and biomarker development and evaluation.
For applicants or administrators trying to locate the full text, the announcement points to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-13-174.html. For access or technical issues with the electronic posting, the contact provided is the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV), which is aimed at troubleshooting announcement access and linking problems rather than scientific program questions.
FAQs: PAR-13-174 (NCI) - Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection
What is this funding opportunity (PAR-13-174) about?
This opportunity supports revision applications to certain existing NCI-funded P50 center awards. The goal is to let established P50 programs add a new, well-justified project that expands the parent program while staying aligned with the original program theme and goals. The scientific focus is early cancer detection by integrating imaging approaches with biomarker approaches.
Is this opportunity for new centers or only for existing P50 awardees?
It is not for creating brand-new centers. It is specifically for revision applications (often described as supplements or competitive revisions) submitted by centers that already hold certain NCI P50 awards.
Which existing P50 programs are eligible to submit a revision under this FOA?
Only currently funded SPOREs (Specialized Programs of Research Excellence) or ICMIC Specialized Centers supported through the NCI P50 mechanism are eligible to apply for this revision opportunity.
What is the primary scientific emphasis of the revision project?
The emphasis is improving cancer screening, early detection, and diagnostic decision-making by combining imaging and biomarker approaches in a coordinated, integrated way.
What does "integration" mean in the context of this FOA?
Integration is described as a core expectation. The revision project is expected to bring together multimodality imaging strategies (using more than one imaging platform or technique in a complementary way) with multiplexed biomarker methodologies (methods that measure multiple biomarkers at once), and to develop, test, and interpret imaging and biomarker signals as a unified detection strategy rather than separate tools.
What kinds of imaging approaches are contemplated here?
The FOA highlights multimodality imaging strategies, meaning approaches that combine more than one imaging platform or technique in a complementary manner, as part of an integrated early-detection strategy with biomarkers.
What kinds of biomarker approaches are contemplated here?
The FOA emphasizes multiplexed biomarker methodologies that can measure multiple biomarkers at once, potentially using biospecimens such as blood, tissue, urine, saliva, or other sample types.
What is the intended outcome of combining imaging and biomarkers?
The intent is to strengthen early cancer detection by developing and evaluating imaging and biomarker signals together, potentially improving sensitivity and specificity for early lesions and refining how combined signals guide diagnostic decision-making.
What exactly is being added to the parent P50 award through this revision?
The revision is intended to add an additional project to the existing P50 program. The added project should meaningfully broaden the parent award's scope and capabilities while remaining clearly aligned with the parent program's theme and goals.
What are examples of activities the added project might support?
Examples mentioned include developing new combined imaging-biomarker workflows, validating integrated detection algorithms, improving sensitivity and specificity for early lesions, or refining how imaging and biomarkers together guide diagnosis.
What is the funding mechanism and type of support?
This is an NIH/NCI discretionary grant opportunity using the NCI P50 mechanism for revision applications tied to cancer detection and diagnosis research.
What is the CFDA number associated with this opportunity?
The activity area is identified as cancer detection and diagnosis research under CFDA 93.394.
Is cost sharing or matching required?
No. Cost sharing or matching is not required for this opportunity.
What is the maximum award amount (award ceiling)?
The announcement lists an award ceiling of $150,000, indicating the maximum funding amount anticipated under this revision mechanism.
Which organization types are listed as eligible applicants?
The FOA lists a wide range of eligible organization types under NIH rules, including public and private institutions of higher education; nonprofits (including 501(c)(3) organizations); state and local governments; tribal governments and tribal organizations; independent school districts; public housing authorities/Indian housing authorities; special district governments; and for-profit organizations (including small businesses). It also explicitly includes categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and Asian American and Native American Pacific Islander-serving institutions, as well as faith-based or community-based organizations and eligible federal agencies.
If many organization types are eligible, why is eligibility still considered narrow?
Because the key eligibility condition is not just organization type. The applicant must already be a currently funded SPORE or ICMIC Specialized Center supported through the NCI P50 mechanism and must be submitting a revision under this FOA.
Are foreign institutions eligible to apply?
No. Non-U.S. (foreign) institutions cannot apply under this FOA.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed in the project?
No. Foreign components are not allowed as defined by the NIH Grants Policy Statement.
When was this FOA posted and what were the key dates?
The FOA was posted and created on April 11, 2013. The original and current closing date was July 10, 2013. The archive date is August 10, 2013.
Is this opportunity still open for applications?
No. Based on the dates provided, it was a time-limited announcement that is now archived.
Where can someone find the full text of the announcement?
The full NIH Grants Guide posting is available at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-174.html
Who is the contact for access or technical issues with the electronic posting?
The contact listed for access or technical issues is the NIH Office of Extramural Research webmaster: FBOWebmaster@OD.NIH.GOV. This contact is described as being for troubleshooting announcement access and linking problems rather than scientific program questions.
Does the FOA provide a scientific/program contact in the information shown here?
No scientific program contact is provided in the information included here. The only contact listed in the provided text is for access or technical issues with the electronic posting.
Browse more opportunities from the same category: Education Health
Next opportunity: Revision Applications to R01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (R01)
Previous opportunity: Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 174
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 174) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications to R01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 172 Funding Number: PAR 13 172 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to U01 Awards on Detection of Pathogen Induced Cancer (DPIC) (U01) Apply for PAR 13 173 Funding Number: PAR 13 173 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 175 Funding Number: PAR 13 175 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 170 Funding Number: PAR 13 170 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 171 Funding Number: PAR 13 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Paul Calabresi Career Development Award for Clinical Oncology (K12) Apply for PAR 13 201 Funding Number: PAR 13 201 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R01) Apply for PA 13 210 Funding Number: PA 13 210 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R21) Apply for PA 13 211 Funding Number: PA 13 211 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Measurement Tools for Community Engaged Research Efforts (R01) Apply for PA 13 209 Funding Number: PA 13 209 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Measurement Tools for Community Engaged Research Efforts (R21) Apply for PA 13 212 Funding Number: PA 13 212 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Limited Competition Fogarty HIV Research Training Program for Low and Middle Income Country Institutions (D43) Apply for PAR 13 126 Funding Number: PAR 13 126 Agency: National Institutes of Health Category: Education Health Funding Amount: $282,000 |
| Medications Development Centers of Excellence Cooperative Program (U54) Apply for RFA DA 14 004 Funding Number: RFA DA 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01) Apply for RFA DA 14 005 Funding Number: RFA DA 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21) Apply for RFA DA 14 006 Funding Number: RFA DA 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integration and Analysis of Diverse HIV Associated Data (R03) Apply for RFA MH 14 200 Funding Number: RFA MH 14 200 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 13 222 Funding Number: PAR 13 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY14 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 14 008 Funding Number: RFA DA 14 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Integrating Substance Abuse Prevention and Treatment within HIV/AIDS Service Delivery Settings (R01) Apply for RFA DA 14 011 Funding Number: RFA DA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| HIV/AIDS and Substance Use among Black/African American Women and Young MSM (R01) Apply for RFA DA 14 010 Funding Number: RFA DA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS and Substance Use Among the Homeless and Unstably Housed (R01) Apply for RFA DA 14 009 Funding Number: RFA DA 14 009 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 174", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.